These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20170027)

  • 21. P2Y receptor antagonists in thrombosis.
    Boeynaems JM; van Giezen H; Savi P; Herbert JM
    Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
    Capodanno D; Dharmashankar K; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):151-8. PubMed ID: 20136601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal antithrombotic treatment for percutaneous coronary intervention.
    Kadakia RA; Ferguson JJ
    Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [What's new on antithrombotics?].
    Helft G; Leger P
    Ann Cardiol Angeiol (Paris); 2009 Aug; 58(4):230-5. PubMed ID: 18950743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prevention of thromboembolism in non-rheumatic atrial fibrillation: an update].
    Pengo V; De Caterina R
    Ital Heart J Suppl; 2001 Sep; 2(9):972-9. PubMed ID: 11675834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The platelet P2 receptors in thrombosis.
    Gachet C; Hechler B
    Semin Thromb Hemost; 2005 Apr; 31(2):162-7. PubMed ID: 15852219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New developments in antithrombotic care].
    Wautrecht JC
    Rev Med Brux; 2009 Sep; 30(4):392-8. PubMed ID: 19899386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents.
    Yandrapalli S; Andries G; Gupta S; Dajani AR; Aronow WS
    Expert Opin Investig Drugs; 2019 Mar; 28(3):223-234. PubMed ID: 30580647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
    Steffel J; Lüscher TF
    J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):616-23. PubMed ID: 19561526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes.
    Doggrell SA
    IDrugs; 2009 May; 12(5):309-17. PubMed ID: 19431096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New oral anticoagulants in atrial fibrillation.
    Turpie AG
    Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New anticoagulant strategies.
    Weitz J; Hirsh J
    J Lab Clin Med; 1993 Oct; 122(4):364-73. PubMed ID: 8228551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging anticoagulants: mechanism of action and future potential.
    Klement P; Rak J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk associated with interruption of antiplatelet and oral anticoagulation therapy.
    Ferreira JS; Gil VM
    Rev Port Cardiol; 2009; 28(7-8):845-58. PubMed ID: 19894663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
    May AE; Geisler T; Gawaz M
    Thromb Haemost; 2008 Mar; 99(3):487-93. PubMed ID: 18327396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Historical Hallmarks of Anticoagulation and Antiplatelet Agents.
    Tsoucalas G; Chevallier J; Karamanou M; Papaioannou T; Sgantzos M; Androutsos G
    Curr Pharm Des; 2016; 22(13):1857-61. PubMed ID: 26750139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.